Global Heart Hub IPEC2 Findings
Analysis based on 7 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026
The findings from the Global Heart Hub's IPEC2 study highlight significant gaps in the diagnosis and treatment of cardiovascular disease in women. This could lead to increased demand for improved diagnostic tools, patient education programs, and gender-specific therapies, potentially impacting pharmaceutical companies like Amgen, Daiichi Sankyo, and Novartis that supported the study, as well as the broader healthcare industry.
Global Heart Hub released preliminary findings from its IPEC2 study at the European Society of Endocrinology's ACNAP Congress 2026. The research, supported by Amgen Inc., Daiichi Sankyo Europe, and Novartis Pharmaceuticals Corporation, reveals that women often delay seeking medical help for heart symptoms and face ongoing challenges in diagnosis due to under-recognition of symptoms, life factors, and clinician bias. Professor Vijay Kunadian and Neil Johnson emphasized that these delays lead to later treatment and diminished outcomes for women, despite cardiovascular disease being the leading cause of death among them globally. The study, which collected data from women in the United States, Canada, China, and Italy, calls for improved symptom recognition and patient education to ensure more equitable and patient-centered cardiovascular care.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard